FDA Approves Alzheimer’s Drug for First Time in Years | Beaufort County Now | The Food and Drug Administration approved a new drug for Alzheimer’s disease Monday

Coronavirus Disease 2019 (COVID-19)
Publisher's Note: This post appears here courtesy of the The Daily Wire. The author of this post is Eric Quintanar.

    The Food and Drug Administration approved a new drug for Alzheimer's disease Monday, purportedly giving doctors a new but much-debated method of directly addressing the Alzheimer's disease process instead of merely treating the symptoms of it.

    The drug, called aducanumab, was approved through the FDA's accelerated approval program, which is reserved for drugs that "fill an unmet medical need based on a surrogate endpoint" but that do not definitively improve patient outcomes. As Stat News notes, this means that, while the drug has shown it can eliminate the toxic protein clumps experts believe contribute to dementia, the regulatory agency doesn't know definitively if it actually helps improve cognition in the patients who receive it.

    "Alzheimer's disease is a devastating illness that can have a profound impact on the lives of people diagnosed with the disease as well as their loved ones," said Patrizia Cavazzoni, M.D., director of the FDA's Center for Drug Evaluation and Research. "Currently available therapies only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's. As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research and innovation."

    According to The New York Times, both proponents and critics of the drug, which also goes by the brand name Aduhelm, agree that it "substantially reduces levels of amyloid," a protein that "clumps into plaques in the brains of Alzheimer's patients and is considered a biomarker of the disease." But in the past, drugs that have reduced amyloid levels in patients have still failed to improve outcomes in patients.

    "There's so little evidence for effectiveness," said Dr. Lon Schneider, director of the California Alzheimer's Disease Center at the University of Southern California, who helped conduct one of the aducanumab trials, told the New York Times. He added: "I don't know what caught the F.D.A.'s fancy here."

    But Harry Johns, chief executive of the Alzheimer's Association, called the approval a "victory for people living with Alzheimer's and their families."

    "This is the first FDA-approved drug that delays decline due to Alzheimer's disease," said Johns in a statement. "This means individuals may have more time to actively participate in daily life, have sustained independence and hold on to memories longer. We can experience longer — the relationships we hold most dear — our families and friends."

    From Stat News:

  • For decades, scientists who study Alzheimer's have focused much of their research on amyloid. A succession of companies including Eli Lilly, Pfizer, Roche, and Merck have attempted to treat Alzheimer's with various types of antibody drugs that work by targeting and eliminating beta-amyloid — all without success.
  • Biogen believed it could succeed where the others failed; it designed Aduhelm to be more potent and therefore better able to eliminate amyloid plaques than earlier drugs. The company also focused on administering Aduhelm to people with mild cognitive impairment or the earliest signs of Alzheimer's, before brain cells were too damaged to stem the tide of the disease.

    An FDA advisory committee voiced opposition to the drug's approval in November. However, the FDA isn't required to listen to the committee.

    Biogen, the maker of the drug, has estimated it will list at $56,000 per year — which does not necessarily reflect the actual price patients or insurance will pay. According to Stat News, analysts believe the price will be between $10,000 and $25,000 per year for patients. The drug is administered intravenously once every four weeks.

    Michel Vounatsos, CEO of Biogen, defended the price of the drug Monday, reportedly telling CNBC that the list price was "fair." He also called the drug the product of "two decades of innovation." The last Alzheimer's drug was approved by the FDA in 2003.

    "We feel a great sense of purpose and responsibility to turn the hope of today's FDA approval of [Aduhelm] into a reality for people living with Alzheimer's disease and their families," said Alisha Alaimo, President of Biogen U.S. "We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible."

    Under the FDA accelerated approval rules, the drug-maker will still need to conduct stage IV clinical trials to prove that Aduhelm provides a clinical benefit to Alzheimer's patients. "If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug," notes the FDA. "If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market."
Go Back


Latest Op-Ed & Politics

We will offer this allotment of three with more to come; some old, most new, but all quite informative, and, moreover, necessary to understanding that in North Carolina, there is a wiser path to govern ourselves and our People.
Comedian and actor Damon Wayans last week praised Dave Chappelle for his Netflix special “The Closer,” saying the politically incorrect content “freed the slaves,” referring to fellow comedians feeling trapped to perform within the confines of the Left’s terms, lest they be canceled.
I have been following the Sheppard case and the Franks case the last couple of years with a somewhat dispassionate interest. The wheels of justice grind and they do grind slow.
A judge appointed by former Democrat President Barack Obama issued an order on Wednesday blocking Texas’ pro-life law that protects unborn babies.
Supporters of Madison Cawthorn have conducted a poll in the newly-drawn 13th Congressional District, a district east of his current one that includes part of Mecklenburg County, with all of Gaston, Polk, Rutherford, McDowell and Burke.
Two more Democrats have announced their plans to retire and not seek re-election in the 2022 midterms, potentially shrinking House Speaker Nancy Pelosi’s (D-CA) already slim majority.


Intercollegiate sports, particularly football and basketball, have ever so slowly, over the years, inserted themselves insidiously into the fabric of most universities with the support of alumni, the business community, and their college presidents.
White House Press Secretary Jen Psaki said during Wednesday’s press briefing that John Kerry didn’t actually mean what he said when he claimed during an interview this week that President Joe Biden “literally” did not know what was happening with the recent crisis involving France.
So far this year, Gov. Cooper has pledged over $930.7 million in tax incentives to just 22 corporations, including $845.8 million over four decades to Apple
The Beaufort County Commissioners will get another bite at the patriotic apple, a fruit they far too often hold in great disdain, to pass this necessary resolution.
Marty Kotis said he was simply trying to start a public discussion when he proposed a motion related to anti-discrimination policies.
On Wednesday, Dr. Elana Yaron Fishbein, the founder of the group No Left Turn in Education, blasted the Biden administration’s DOJ after the Biden Justice Department ordered the FBI to investigate alleged “threats” against school board members and teachers.


President Biden's numbers in the Tar Heel State are in the gutter. According to a recent High Point University poll, Biden's approval rating is at a lowly 35 percent.


Back to Top